MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy

Cancer Discovery

Volumn 6, Issue 1, 2016, Pages 45-58

  Neupane, Manish ^a,b   Clark, Allison P ^a,b   Landini, Serena ^a   Birkbak, Nicolai J ^c   Eklund, Aron C ^c   Lim, Elgene ^d   Culhane, Aedin C ^e   Barry, William T ^e   Schumacher, Steven E ^a,f   Beroukhim, Rameen ^a,b,f   Szallasi, Zoltan ^b,c   Vidal, Marc ^a,b   Hill, David E ^a,b   Silver, Daniel P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; LUCIFERASE; METHYL CPG BINDING PROTEIN 2; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; ISOPROTEIN; MECP2 PROTEIN, HUMAN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DNA BINDING; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE RAS; PROTEIN BINDING; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; X CHROMOSOME; ALTERNATIVE RNA SPLICING; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOUSE; NEOPLASM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; CYTOSINE; EPIGENESIS, GENETIC; GENE AMPLIFICATION; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTEIN ISOFORMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84954055981     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0341     Document Type: Article

References (70)

1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
2. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
4. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-8.
5. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15: 50-65.
6. Yang X, Boehm JS, Yang X, Salehi-Ashtiani K, Hao T, Shen Y, et al. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 2011; 8: 659-61.
7. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23: 185-8.
8. Meehan RR, Lewis JD, McKay S, Kleiner EL, Bird AP. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 1989; 58: 499-507.
9. Nan XX, Ng HHH, Johnson CAC, Laherty CDC, Turner BMB, Eisenman RNR, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-9.
10. Jordan C, Li HH, Kwan HC, Francke U. Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets. BMC Med Genet 2007; 8: 36.
11. Chahrour MM, Jung SYS, Shaw CC, Zhou XX, Wong STCS, Qin JJ, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science (New York, NY) 2008; 320: 1224-9.
12. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012; 151: 1417-30.
13. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2: S4-11.
14. Weisenberger DJ. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest 2014; 124: 17-23.
15. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin ? Cancer Cell 2012; 22: 9-20.
16. Stampfer MR. Isolation and growth of human mammary epithelial cells. Methods Cell Sci 1985; 9: 107-15.
17. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 2002; 9: 1155-62
18. Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 2005; 65: 703-7.
19. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005; 65: 919-24.
20. Yokota N, Mainprize TG, Taylor MD, Kohata T, Loreto M, Ueda S, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004; 23: 3444-53.
21. Michiels EM, Oussoren E, Van Groenigen M, Pauws E, Bossuyt PM, Voute PA, et al. Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics 1999; 1: 83-91.
22. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007; 104: 20007-12.
23. Hoffbuhr KC, Moses LM, Jerdonek MA, Naidu S, Hoffman EP. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. Ment Retard Dev Disabil Res Rev 2002; 8: 99-105.
24. Derose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17: 1514-20.
25. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007; 12: 160-70.
26. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 2000; 47: 670-9.
27. Yusufzai TM, Wolffe AP. Functional consequences of Rett syndrome mutations on human MeCP2. Nucleic Acids Res 2000; 28: 4172-9.
28. Free A, Wakefield RI, Smith BO, Dryden DT, Barlow PN, Bird AP. DNA recognition by the methyl-CpG binding domain of MeCP2. J Biol Chem 2001; 276: 3353-60.
29. Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 2008; 70: 868-75.
30. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15: 489-500.
31. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-34.
32. Cancer Genome Atlas Research Network. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
33. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371-5.
34. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008; 105: 6584-9.
35. Spangle JM, Munger K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathogens 2013; 9: e1003237.
36. Taylor SJ, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol 1996; 6: 1621-7.
37. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003; 3: 483-95.
38. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A, et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A 2006; 103: 16296-300.
39. Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, et al. FAM83B mediates EGFR-and RAS-driven oncogenic transformation. J Clin Invest 2012; 122: 3197-210.
40. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005; 121: 837-48.
41. Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, et al. Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biol 2014; 12: 20.
42. Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. Identification of an oncogenic RAB protein. Science 2015; 350: 211-7.
43. Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Loven J, et al. Global transcriptional and translational repression in human-embryonic-stemcell-derived Rett syndrome neurons. Cell Stem Cell 2013; 13: 446-58.
44. Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 2011; 20: 1182-96.
45. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006; 49: 341-8.
46. Itoh M, Ide S, Takashima S, Kudo S, Nomura Y, Segawa M, et al. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. J Neuropathol Exp Neurol 2007; 66: 117-23.
47. Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 2009; 106: 2029-34.
48. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-4.
49. Crespi B. Autism and cancer risk. Autism Res 2011; 4: 302-10.
50. Kent L, Bowdin S, Kirby GA, Cooper WN, Maher ER. Beckwith Weidemann syndrome: a behavioral phenotype-genotype study. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1295-7.
51. Marui T, Hashimoto O, Nanba E, Kato C, Tochigi M, Umekage T, et al. Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population. Am J Med Genet B Neuropsychiatr Genet 2004; 131B: 43-7.
52. Gillberg C, Forsell C. Childhood psychosis and neurofibromatosis-more than a coincidence? J Autism Dev Disord 1984; 14: 1-8.
53. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005; 42: 318-21.
54. Greer JM, Wynshaw-Boris A. Pten and the brain: sizing up social interaction. Neuron 2006; 50: 343-5.
55. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. Am J Med Genet Part A 2007; 143: 589-93.
56. McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res 2010; 3: 137-41.
57. Varga EA, Pastore M, Prior T, Herman GE, McBride KL. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 2009; 11: 111-7.
58. Harrison JE, Bolton PF. Annotation: tuberous sclerosis. J Child Psychol Psychiatry 1997; 38: 603-14.
59. Serajee FJ, Nabi R, Zhong H, Mahbubul Huq AH. Association of INPP1, PIK3CG, and TSC2 gene variants with autistic disorder: implications for phosphatidylinositol signalling in autism. J Med Genet 2003; 40: e119.
60. Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A 2006; 103: 16834-9.
61. Houge G, Rasmussen IH, Hovland R. Loss-of-Function CNKSR2 Mutation Is a Likely Cause of Non-Syndromic X-Linked Intellectual Disability. Mol Syndromology 2012; 2: 60-3.
62. Castro J, Garcia RI, Kwok S, Banerjee A, Petravicz J, Woodson J, et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc Natl Acad Sci U S A 2014; 111: 9941-6.
63. Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y, et al. Safety, pharmacokinetics, and preliminary assessment of effi-cacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A 2014; 111: 4596-601.
64. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-5.
65. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-33.
66. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836-52.
67. Huang H, Jiang X, Li Z, Li Y, Song CX, He C, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 2013; 110: 11994-9.
68. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621-5.
69. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
70. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134-40.